A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of CU-20401 for Injection in Moderate to Severe Contour Protuberance or Excessive Enrichment Due to Submental Fat (SMF) Accumulation
Latest Information Update: 28 Jan 2025
At a glance
- Drugs CU-20401 (Primary)
- Indications Subcutaneous fat disorders
- Focus Therapeutic Use
- Sponsors Cutia Therapeutics
Most Recent Events
- 22 Jan 2025 Status changed from active, no longer recruiting to completed.
- 11 Jun 2024 Status changed from recruiting to active, no longer recruiting.
- 09 Jan 2024 New trial record